Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
6.07
-0.14 (-2.25%)
At close: May 30, 2025, 4:00 PM
6.07
0.00 (0.00%)
Pre-market: Jun 2, 2025, 9:03 AM EDT
Amicus Therapeutics Revenue
Amicus Therapeutics had revenue of $125.25M in the quarter ending March 31, 2025, with 13.45% growth. This brings the company's revenue in the last twelve months to $543.14M, up 28.25% year-over-year. In the year 2024, Amicus Therapeutics had annual revenue of $528.30M with 32.29% growth.
Revenue (ttm)
$543.14M
Revenue Growth
+28.25%
P/S Ratio
3.42
Revenue / Employee
$1,088,459
Employees
499
Market Cap
1.87B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 528.30M | 128.94M | 32.29% |
Dec 31, 2023 | 399.36M | 70.12M | 21.30% |
Dec 31, 2022 | 329.23M | 23.72M | 7.76% |
Dec 31, 2021 | 305.51M | 44.63M | 17.11% |
Dec 31, 2020 | 260.89M | 78.65M | 43.16% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
FOLD News
- 3 days ago - Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 - GlobeNewsWire
- 26 days ago - Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference - GlobeNewsWire
- 4 weeks ago - Amicus Therapeutics, Inc. (FOLD) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates - GlobeNewsWire
- 4 weeks ago - Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States - GlobeNewsWire
- 6 weeks ago - Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025 - GlobeNewsWire
- 2 months ago - Amicus Therapeutics Is Very Attractive At Current Prices (Rating Upgrade) - Seeking Alpha
- 3 months ago - In NCLA Amicus Win, D.C. Circuit Recognizes President Trump's Right to Fire Principal Officer - GlobeNewsWire